| Dr Daniel Joseph Livorsi, MD | |
|
200 Hawkins Dr, Sw54-13 Gh, Iowa City, IA 52242-1009 | |
| (319) 356-7740 | |
| Not Available |
| Full Name | Dr Daniel Joseph Livorsi |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 19 Years |
| Location | 200 Hawkins Dr, Iowa City, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720240237 | NPI | - | NPPES |
| 201023170 | Medicaid | IN |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Iowa Hospital & Clinics | Iowa city, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| State University Of Iowa | 7618884230 | 1476 |
News Archive
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 1b study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism, which is a frequent and serious complication of end-stage renal disease.
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
Type 2 diabetes patients who fail to properly control their blood pressure within a year of being diagnosed with hypertension face an elevated risk for future major cardiovascular events for up to 3 years subsequently, study results show.
A set of consensus recommendations identifying top research priorities related to female pelvic floor disorders is presented in the January/February issue of Female Pelvic Medicine & Reconstructive Surgery, official journal of The American Urogynecologic Society.
Blood collection professionals will be recognized in communities worldwide September 13-19, 2009, as part of the 5th Annual Blood Collectors Week, sponsored jointly by Fenwal, Inc. and AABB (formerly known as the American Association of Blood Banks). During the week, blood centers across the country will host celebrations, often with local government officials, to recognize their staffs and donors.
› Verified 3 days ago
| Entity Name | State University Of Iowa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477554814 PECOS PAC ID: 7618884230 Enrollment ID: O20031107000060 |
News Archive
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 1b study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism, which is a frequent and serious complication of end-stage renal disease.
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
Type 2 diabetes patients who fail to properly control their blood pressure within a year of being diagnosed with hypertension face an elevated risk for future major cardiovascular events for up to 3 years subsequently, study results show.
A set of consensus recommendations identifying top research priorities related to female pelvic floor disorders is presented in the January/February issue of Female Pelvic Medicine & Reconstructive Surgery, official journal of The American Urogynecologic Society.
Blood collection professionals will be recognized in communities worldwide September 13-19, 2009, as part of the 5th Annual Blood Collectors Week, sponsored jointly by Fenwal, Inc. and AABB (formerly known as the American Association of Blood Banks). During the week, blood centers across the country will host celebrations, often with local government officials, to recognize their staffs and donors.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Joseph Livorsi, MD 200 Hawkins Dr, Sw54-13 Gh, Iowa City, IA 52242-1009 Ph: () - | Dr Daniel Joseph Livorsi, MD 200 Hawkins Dr, Sw54-13 Gh, Iowa City, IA 52242-1009 Ph: (319) 356-7740 |
News Archive
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced enrollment of the first patients in a Phase 1b study of KAI-4169, a novel pharmaceutical agent being tested for the treatment of secondary hyperparathyroidism, which is a frequent and serious complication of end-stage renal disease.
Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).
Type 2 diabetes patients who fail to properly control their blood pressure within a year of being diagnosed with hypertension face an elevated risk for future major cardiovascular events for up to 3 years subsequently, study results show.
A set of consensus recommendations identifying top research priorities related to female pelvic floor disorders is presented in the January/February issue of Female Pelvic Medicine & Reconstructive Surgery, official journal of The American Urogynecologic Society.
Blood collection professionals will be recognized in communities worldwide September 13-19, 2009, as part of the 5th Annual Blood Collectors Week, sponsored jointly by Fenwal, Inc. and AABB (formerly known as the American Association of Blood Banks). During the week, blood centers across the country will host celebrations, often with local government officials, to recognize their staffs and donors.
› Verified 3 days ago
Rami G. El Abiad, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-4901 Fax: 319-384-8559 | |
Grerk Sutamtewagul, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Dept Of Internal Medicine, Iowa City, IA 52242 Phone: 319-356-1616 Fax: 319-353-8383 | |
Dr. Kaleb Tanner Veit, D.O. Infectious Disease Medicare: Medicare Enrolled Practice Location: 200 Hawkins Drive, Iowa City, IA 52242 Phone: 319-353-6239 Fax: 319-353-6406 | |
Dr. Elizabeth R Bowen, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 200 Hawkins Dr, Department Of Internal Medicine, Iowa City, IA 52242 Phone: 319-353-7842 Fax: 319-353-7850 | |
Balarama Krishna Surapaneni, Infectious Disease Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-4019 Fax: 319-353-8073 | |
Soorih Shaikh, MD Infectious Disease Medicare: Medicare Enrolled Practice Location: 200 Hawkins Dr, Iowa City, IA 52242 Phone: 319-356-2148 Fax: 319-353-8383 | |
Dr. Richard Ellis Larew, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 2460 Towncrest Dr, Iowa City, IA 52240 Phone: 319-338-7862 |